Nebilet (Nebivolol)

Nebivolol works by selectively blocking β1‑adrenergic receptors in the heart, which slows heart rate and reduces contractile force. It also stimulates endothelial nitric‑oxide production, causing vasodilation and lowering peripheral vascular resistance. The combined actions lower arterial pressure while preserving β2‑mediated bronchodilation.

The dose of nebivolol is individualized. A qualified prescriber determines the appropriate starting dose, titration schedule, and maintenance dose based on the patient’s clinical condition, age, renal function and response to therapy. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for nebivolol in pregnancy are limited, and the drug is generally avoided unless the potential benefit justifies the risk. It is excreted in breast‑milk, so breastfeeding mothers should discuss alternatives with their physician, as the risk to the infant is not well established.

To request Nebilet, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nebivolol is a third‑generation, β1‑selective blocker that also promotes nitric‑oxide‑mediated vasodilation, giving it a more favourable metabolic profile and fewer bronchospastic effects compared with non‑selective agents. It may be preferred in patients who need blood‑pressure control without compromising peripheral circulation or respiratory function.

Nebilet tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Nebilet is taken orally, usually once daily, with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless the prescriber specifically advises an alternative method.

Serious adverse events include severe bradycardia, heart block, worsening heart failure, bronchospasm in patients with reactive airway disease, and rare cases of hepatic dysfunction or severe allergic reactions. Patients should seek immediate medical attention if they experience fainting, rapid weight gain, difficulty breathing, or signs of an allergic reaction.

Nebilet is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia (heart rate <50 bpm), second‑ or third‑degree atrioventricular block, cardiogenic shock, or decompensated heart failure. Caution is also advised for individuals with uncontrolled asthma, severe peripheral vascular disease, or significant hepatic impairment.